開発者の論文リスト

Waalsの開発者は、大学や研究機関の先生方、企業の研究者の方と研究をご一緒させて頂いています。

これまでに、立体構造を活用する事で新しい結果に繋がる研究をいくつも経験しました。皆様に感謝いたします。

1.

Structural modeling and mutagenesis of endo-β-N-acetylglucosaminidase from Ogataea minuta identifies the importance of Trp295 for hydrolytic activity.

Kitajima T, Jia Y, Komatsuzaki A, Cui J, Matsuzawa F, Aikawa SI, Gao XD, Chiba Y.

J Biosci Bioeng. 2018 Feb;125(2):168-174. PMID: 28903882


2.

Inhibitory effects and specificity of synthetic sialyldendrimers toward recombinant human cytosolic sialidase 2 (NEU2).

Rahman MM, Kitao S, Tsuji D, Suzuki K, Sakamoto J, Matsuoka K, Matsuzawa F, Aikawa S, Itoh K.

Glycobiology. 2013 Apr;23(4):495-504. PMID: 23363739


3.

Introduction of an N-glycan sequon into HEXA enhances human beta-hexosaminidase cellular uptake in a model of Sandhoff disease.

Matsuoka K, Tsuji D, Aikawa S, Matsuzawa F, Sakuraba H, Itoh K.

Mol Ther. 18(8), 1519-1526 (2010)   PMID: 20571546


4.

Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism.

Yoshimizu M, Tajima Y, Matsuzawa F, Aikawa S, Iwamoto K, Kobayashi T, Edmunds T, Fujishima K, Tsuji D, Itoh K, Ikekita M, Kawashima I, Sugawara K, Ohyanagi N, Suzuki T, Togawa T, Ohno K, Sakuraba H.

Clin Chim Acta. 391(1-2), 68-73 (2008)  PMID: 18328816


5.

Phosphorylation-induced conformational switching of CPI-17 produces a potent myosin phosphatase inhibitor.

Eto M, Kitazawa T, Matsuzawa F, Aikawa S, Kirkbride JA, Isozumi N, Nishimura Y, Brautigan DL, Ohki SY.

Structure. 15(12), 1591-1602 (2007)   PMID: 18073109


6.

Structural and biochemical studies on Pompe disease and a "pseudodeficiency of acid alpha-glucosidase".

Tajima Y, Matsuzawa F, Aikawa S, Okumiya T, Yoshimizu M, Tsukimura T, Ikekita M, Tsujino S, Tsuji A, Edmunds T, Sakuraba H.

J Hum Genet. 52(11), 898-906 (2007)   PMID: 17805474


7.

Molecular pathologies of and enzyme replacement therapies for lysosomal diseases.

Sakuraba H, Sawada M, Matsuzawa F, Aikawa S, Chiba Y, Jigami Y, Itoh K.

CNS Neurol Disord Drug Targets. 5(4), 401-413 (2006) Review.   PMID: 16918392


8.

Prediction of the mechanism of action of omuralide (clasto-lactacystin beta-lactone) on human cathepsin A based on a structural model of the yeast proteasome beta5/PRE2-subunit/omuralide complex.

Aikawa S, Matsuzawa F, Satoh Y, Kadota Y, Doi H, Itoh K.

Biochim Biophys Acta. 1764(8), 1372-1380 (2006)   PMID: 16870514


9.

Phospho-pivot modeling predicts specific interactions of protein phosphatase-1 with a phospho-inhibitor protein CPI-17.

Matsuzawa F, Aikawa SI, Ohki SY, Eto M.

J Biochem. 137(5), 633-641 (2005)   PMID: 15944417


10.

Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.

Matsuzawa F, Aikawa S, Doi H, Okumiya T, Sakuraba H.

Hum Genet. 117(4), 317-328 (2005)   PMID: 15924232


11.

Critical regions for assembly of vertebrate nonmuscle myosin II.

Nakasawa T, Takahashi M, Matsuzawa F, Aikawa S, Togashi Y, Saitoh T, Yamagishi A, Yazawa M.

Biochemistry. 44(1), 174-183 (2005)  PMID: 15628858


12.

Three dimensional structural studies of alpha-N-acetylgalactosaminidase (alpha-NAGA) in alpha-NAGA deficiency (Kanzaki disease): different gene mutations cause peculiar structural changes in alpha-NAGAs resulting in different substrate specificities and clinical phenotypes.

Kanekura T, Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Hirabayashi Y, Yoshii N, Fukushige T, Kanzaki T.

J Dermatol Sci. 37(1), 15-20 (2005)    PMID: 15619430


13.

Microbial serine carboxypeptidase inhibitors--comparative analysis of actions on homologous enzymes derived from man, yeast and wheat.

Satoh Y, Kadota Y, Oheda Y, Kuwahara J, Aikawa S, Matsuzawa F, Doi H, Aoyagi T, Sakuraba H, Itoh K.

J Antibiot (Tokyo). 57(5), 316-325 (2004)    PMID: 15303492


14.

Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease).

Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, Nakada H, Fukushige T, Kanzaki T.

J Hum Genet. 49(1), 1-8 (2004)    PMID: 14685826


15.

Structural basis of the GM2 gangliosidosis B variant.

Matsuzawa F, Aikawa S, Sakuraba H, Lan HT, Tanaka A, Ohno K, Sugimoto Y, Ninomiya H, Doi H.

J Hum Genet. 48(11), 582-589 (2003)     PMID: 14577003


16.

Molecular and structural studies of the GM2 gangliosidosis 0 variant.

Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, Lin H, Ohno K, Tanaka A, Yamada H, Uyama E.

J Hum Genet. 47(4), 176-183 (2002)    PMID: 12166653


17.

Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes.

Itoh K, Naganawa Y, Matsuzawa F, Aikawa S, Doi H, Sasagasako N, Yamada T, Kira J, Kobayashi T, Pshezhetsky AV, Sakuraba H.

J Hum Genet. 47(1), 29-37 (2002)    PMID: 11829139


18.

Bcl-2 antiapoptotic protein mediates verotoxin II-induced cell death: possible association between bcl-2 and tissue failure by E. coli O157:H7.

Suzuki A, Doi H, Matsuzawa F, Aikawa S, Takiguchi K, Kawano H, Hayashida M, Ohno S.

Genes Dev. 14(14), 1734-1740 (2000)   PMID: 10898788 


19.

Actin-actin contact: chemical cross-linking between actin and the 2.6-kDa peptide from subdomain 4 of actin.

Hori K, Morita F, Matsuzawa F, Aikawa S.

J Biochem. 118(6), 1232-1238 (1995)   PMID: 8720140


20.

Diverse incidences of individual oligopeptides (dipeptidic to hexapeptidic) in proteins of human, bakers' yeast, and Escherichia coli origin registered in the Swiss-Prot data base.

Doi H, Kitajima M, Watanabe I, Kikuchi Y, Matsuzawa F, Aikawa S, Takiguchi K, Ohno S.

Proc Natl Acad Sci U S A. 92(7), 2879-83 (1995)    PMID: 7708741